Concepedia

Publication | Open Access

PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes

DOIFull Paper Access

430

Citations

16

References

2019

Year

Vanita R. Aroda, Julio Rosenstock, Yasuo Terauchi, Yüksel Altuntaş, Nebojsa M. Lalic, Enrique C. Morales Villegas, Ole Kleist Jeppesen, Erik Christiansen, CHRISTIN L. HERTZ, Martin Haluzı́k
Diabetes Care

Abstract

In patients with type 2 diabetes, oral semaglutide monotherapy demonstrated superior and clinically relevant improvements in HbA<sub>1c</sub> (all doses) and body weight loss (14 mg dose) versus placebo, with a safety profile consistent with other GLP-1 receptor agonists.

References

YearCitations

Page 1